3,4-Dihydro-5-methyl-4-oxo-2-quinazolinecarboxylic acid | 1029420-50-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3,4-Dihydro-5-methyl-4-oxo-2-quinazolinecarboxylic acid
• 英文别名: 5-methyl-4-oxo-3H-quinazoline-2-carboxylic acid
• CAS: 1029420-50-5
• 化学式: C₁₀H₈N₂O₃
• 分子量: 204.18
• InChiKey: HEFYEEZMFHTKNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080261968A1

  公开（公告）日：2008-10-23

  The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

  本发明涉及含有杂环的药物，特别是含有杂环的金属蛋白酶抑制剂。更具体地说，本发明提供了一种新型的杂环MMP-3、MMP-8和/或MMP-13抑制剂，其在与当前已知的MMP-13、MMP-8和MMP-3抑制剂相比具有更高的效力和选择性。
• Metalloprotease inhibitors containing a squaramide moiety
  申请人：Gege Christian

  公开号：US20080221128A1

  公开（公告）日：2008-09-11

  The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• US7713966B2
  申请人：——

  公开号：US7713966B2

  公开（公告）日：2010-05-11
• [EN] HETEROBICYCLIC METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASE HÉTÉROBICYCLIQUE
  申请人：ALANTOS PHARM HOLDING

  公开号：WO2008063668A1

  公开（公告）日：2008-05-29

  [EN] The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
  [FR] L'invention concerne, de manière générale, des agents pharmaceutiques contenant de l'azabicyclique, et notamment des composés inhibant la métalloprotéase azabicyclique. Cette invention concerne plus particulièrement une nouvelle classe de composés inhibant les MMP-3, MMP-8 et/ou MMP-13 azabicycliques, qui offre une puissance et une sélectivité améliorées par rapport aux inhibiteurs de MMP-13, MMP-8 et MMP-3 actuellement connus.
• [EN] METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASE CONTENANT UNE FRACTION SQUARAMIDE
  申请人：ALANTOS PHARM HOLDING

  公开号：WO2008109178A1

  公开（公告）日：2008-09-12

  [EN] The present invention relates generally to pharmaceutical agents of Formula (I) containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP 3, MMP 8 and/or MMP 13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP 13, MMP 8 and MMP 3 inhibitors. Formula (I).
  [FR] De manière générale, l'invention concerne des agents pharmaceutiques représentés par la formule (I) qui contiennent une fraction hétérocyclique, et en particulier, des composés inhibiteurs de métalloprotéase hétérocycliques. Plus particulièrement, la présente invention fournit une nouvelle catégorie de composés inhibiteurs de MMP 3, de MMP 8 et/ou de MMP 13 hétérocycliques pourvus d'une fraction squaramide ou benzoxazinone, qui présentent une efficacité et une sélectivité accrues par rapport aux inhibiteurs de MMP 13, de MMP 8 et de MMP 3 actuellement connus. Formule (I)